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Edited by Laszlo NagyAbstract The ATP-binding cassette transporter A1 (ABCA1)
regulates lipid eﬄux from peripheral cells to High-density lipo-
protein. The platelet-derived growth factor (PDGF) is a potent
mitogen that enables vascular smooth muscle cells to participate
in atherosclerosis. In this report, we showed that PDGF sup-
pressed endogenous expression of ABCA1 in cultured vascular
smooth muscle cells. Exposure of CRL-208 cells to PDGF elic-
ited a rapid phosphorylation of a kinase downstream from PI3-
K, Akt. The constitutively active form of both p110, a subunit of
PI3-K, and Akt inhibited activity of the ABCA1 promoter. In
conclusion, PI3-K-Akt pathways participate in PDGF-suppres-
sion of ABCA1 expression.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Atherosclerotic coronary artery disease (CAD) is a major
public heath burden in developed countries. High-density lipo-
protein (HDL) plays a critical role in cholesterol metabolism
because they mediate a normal physiologic process, the so-
called reverse cholesterol transport (RCT) [1,2]. In this process
HDL particles shuttle cholesterol from extra-hepatic tissues to
the liver for further metabolism and excretion [1]. The ATP-
binding cassette transporter A1 (ABCA1), a 254-kDa mem-
brane protein, is a pivotal regulator of lipid eﬄux from cells
to apolipoproteins [3]. ABCA1 plays an important role in
RCT because mutations of this gene found in patients with
Tangier disease cause impaired eﬄux of lipids to apolipopro-
tein A–I [3].
Abnormal proliferation of vascular smooth muscle cells
(VSMCs) is a critical component of atherosclerosis and arterial
restenosis after angioplasty [4]. The mechanism is believed to
be related to a response to injury in which growth factors such*Corresponding author. Fax: +81 878 91 2147.
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stimulating proliferation and migration of VSMCs to the site
resulting in the formation of a neointima. PDGF bound to
its receptor leads to the activation of several cell-signaling
pathways associated with both VSMC proliferation and
migration, such as those related to mitogen-activated protein
kinase (MAPK), extracellular signal-regulated kinase (ERK)
1/2, phospholipase C-c (PLC-c), and phosphatidylinositol 3-ki-
nase (PI3-k) [5]. Protein kinase B (Akt) activation is dependent
on the upstream kinase PI3-K and inﬂuences cellular functions
by activation of various downstream eﬀectors [6].
In the present study, the results of our studies suggest that
PDGF acts via the PI3-K/Akt signal transduction pathway
to suppress ABCA1 gene transcription.2. Materials and methods
2.1. Material
LY294002, PD98059, Bisindolylmaleimide I were purchased from
Calbiochem (La Jolla, CA). Recombinant rat PDGF-BB was pur-
chased from R&D, Co. Ltd (CA). Antibody: Anti-ABCA1 monoclo-
nal antibody KM3110 was generated against the C-terminal 20
amino acids of ABCA1 in mice. Apolipoprotein A–I (apoA–I) and
acetylated LDL (AcLDL) were purchased from Funakoshi (Osaka,
Japan).
2.2. Plasmid preparation
An expression vector encoding a constitutively active Akt (Akt-CA)
and a dominant-negative mutant of Akt (Akt-DN) was described pre-
viously [7]. An expression vector encoding a constitutively active p110
subunit was gift from J. Downward (Imperial Cancer research Foun-
dation, London, UK). An expression vector encoding a PTEN (phos-
phatase and tensin homologue deleted on chromosome ten) was a gift
from J.E. Dixon (Univ. of Michigan, Arbor, MI).
Cell culture: Primary cultured human vascular smooth muscle cell
was purchased (Applied Cell Biology Research, Kirkland, WA). Rat
vascular smooth muscle cell line, CRL-2018 (obtained from ATCC,
Manassas, VA) was grown in DMEM (Life Technologies, Tokyo,
Japan) supplemented with 10% FCS.
2.3. Western blot analysis
The proteins were resuspended under reducing conditions and a
15 lg was fractionated by size on 7.5% SDS–polyacrylamide gels [8].
The membranes were blocked overnight at room temperature with
0.1% Tween 20 in PBS (PBS-T) containing anti-ABCA1 antibody
KM3110 (diluted 1:5000 from whole antiserum). These membranesblished by Elsevier B.V. All rights reserved.
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PBS-T containing horseradish peroxidase-linked anti-mouse IgG
(diluted 1/3000), rinsed in PBS-T.
2.4. Transfection of CRL-2018 cells and luciferase reporter gene assay
The reporter construct contained the ABCA1 gene sequence span-
ning the region from 919 to +224 as determined from the published
sequence [8]. The segment of interest was ampliﬁed using PCR and
cloned into the luciferase reporter gene (pABCA1-LUC). Puriﬁed re-
porter plasmid was transfected into CRL-2018 cells using a conven-
tional cationic liposome transfection method (Lipofectamine, Life
Technologies, Gaithersburg, MD). All assays were corrected for b-
galactosidase activity and total amount of protein in each reaction
was identical as previously described [9].
2.5. Immunoblotting of Akt
Akt phosphorylated at Ser473 or Thr308 was detected using a phos-
pho-speciﬁc Akt polyclonal antibody and total Akt was detected by
using phosphorylation-independent antibodies (Upstate biotechnol-
ogy, NY) as described previously [10]. The protein bands were visual-
ized by chemiluminescence.
2.6. Cholesterol eﬄux assay
The cells were labeled with 3H-cholesterol (5 lCi/ml) incorporated
into acetylated LDL (AcLDL) (30 lg AcLDL/ml). Cells underwent
an equilibration step in media plus 2 mg/ml bovine serum albumin
(BSA) for 12 h prior to eﬄux. After the equilibration period, cells were
incubated with apoA–I (30 lg/ml) in DMEM/BSA for 5 h. 3H-choles-
terol eﬄux was expressed as medium [3H] cholesterol radioactivity as a
percentage of total [3H] cholesterol radioactivity [11].
2.7. Statistical analysis
Statistical comparisons were made possible through the use of one-
way analysis of variance and Student’s t-test, with P < 0.05 considered
signiﬁcant.Fig. 1. Eﬀect of PDGF on ABCA1 expression in CRL-2018 cells. (A,B) P
muscle cells (A) or CRL-2018 cells (B) were exposed to PDGF for 24 h an
analysis probed with an anti-ABCA1 antibody. (C) No-treatment or p: 10 ng
for each treatment group is shown on the right. The asterisk denotes a sign3. Results
3.1. PDGF decreases ABCA1 expression in CRL-2018 cells
To test whether PDGF aﬀected ABCA1 expression, we used
Western blot analysis to measure the levels of endogenous
ABCA1 expression in both primary cultured human smooth
muscle cell and cell line, CRL-2018. Exposure of the cells to
PDGF for 24 h decreased the abundance of endogenous
ABCA1 protein as compared with that in cells maintained in
control media (Fig. 1A and B).
3.2. Eﬀect of PDGF on ABCA1 promoter activity
Next we measured transcriptional activity of the ABCA1
promoter in the CRL-2018 cells. CRL-208 cells transfected
with pABCA1-LUC were exposed to varying concentrations
of PDGF (Fig. 2A). Consistent with the observed changes in
the levels of ABCA1 protein and mRNA, PDGF inhibited
activity of the promoter in a dose dependent fashion with near
maximum inhibition using 10 ng/ml of PDGF. To test whether
protein kinases were involved in the inhibitory actions of
PDGF on ABCA1 promoter activity, we studied the eﬀect of
pharmacological inhibitors on ABCA1 promoter activity.
Therefore, exposure of the pABCA1-LUC transfected CRL-
2018 cells to PDGF (10 ng/ml) was tested in the presence of
inhibitors such as PI3-K (10 lM LY294002), a mitogen-acti-
vated ERK (10 lM PD98059), or PKC (Bisindolylmaleimide
I) to the CRL-2018 cells. Results (Fig. 2B) showed that the
inhibitory eﬀect of PDGF on ABCA1 promoter activity was
not sensitive to inhibitors of ERK or PKC but it was sensitive
to LY294002, an inhibitor of PI3-K.DGF decreases ABCA1 protein expression. Human vascular smooth
d ABCA1 protein in total cell lysate was detected using Western blot
/ml PDGF. A graph showing the mean ± S.E.M. of three experiments
iﬁcant diﬀerence (P < 0.01).
Fig. 2. Eﬀect of PDGF on ABCA1 transcriptional activity and in CRL-2018 cells. (A) PDGF decreases ABCA1 gene transcription. CRL-2018 cells
were transfected with pABCA1-LUC and treated with various concentration of PDGF for 24 h. Each data point shows the means ± S.E.M. of four
separate transfections that were performed on separate days. The asterisk denotes a signiﬁcant (P < 0.01). (B) A PI3-K inhibitor blocks the actions of
PDGF. Eﬀects of a PI3-K inhibitor LY294002 (LY), a MEK1 inhibitor PD98059 (PD), or a protein kinase C inhibitor Bisindolylmaleimide I (BIS)
on PDGF (10 ng/ml)-inhibited ABCA1 transcriptional activity. Values represent the mean of triplicate determinations. The asterisk denotes a
signiﬁcant diﬀerence (P < 0.01).
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To further demonstrate the inhibitory actions of PDGF, we
took advantage of the fact that ABCA1 functions to facilitate
cellular lipid eﬄux to HDL in the presence of ApoA–I [12].
This parameter was assessed by measuring cholesterol eﬄux
from CRL-2018 cells to ApoA–I using 3H-cholesterol deliv-
ered to the cells via acetylated-LDL uptake. We noted thatpretreatment with PDGF (10 ng/ml) for 24 h proved to be
most eﬀective and therefore, all subsequent experiments were
performed under these conditions. PDGF inhibited cholesterol
eﬄux to 75% of control untreated cells (Fig. 3). As predicted
from the preceding studies, LY294002 blocked PDGF-sup-
pression of the cholesterol eﬄux but the PI3-K inhibitor had
no stimulatory eﬀect on basal eﬄux in the absence of PDGF.
Fig. 3. PDGF inhibits cholesterol eﬄux in CRL-2018 cells. CRL-2018 cells were treated with PDGF (10 ng/ml), LY294002 (LY), or both PDGF and
the inhibitor. The cells were incubated with apoA–I (50 lg/ml) in DMEM/BSA for 5 h. ApoA–I speciﬁc [3H] cholesterol eﬄux was calculated and
apoA–I-speciﬁc eﬄux in the absence of any treatment was normalized to 100%. Each individual experiment was performed in quadruplicate and the
values show the mean ± S.E.M. The asterisk denotes a signiﬁcant diﬀerence (P < 0.01). Lane 1; control, lane2; LY294002 (LY), lane 3; PDGF, lane 4;
PDGF and LY294002 (LY).
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The preceding studies showed that PI3-kinase likely partici-
pated in the inhibitory eﬀects of PDGF on ABCA1 expression.
Since Akt is a potential target of the PI3-K, we wondered
whether the use of PDGF could also activate Akt. To answer
this question, we examined the kinetics of Akt activation by
measuring phosphorylation of the residues Thr308 and
Ser473. These sites are modiﬁed as a prerequisite for catalytic
activity of Akt. The results (Fig. 4) showed that Akt phosphor-
ylation was evident within 15 min following exposure of the
CRL-2018 cells to PDGF and this activity reached a peak at
60 min.
3.5. Akt regulates ABCA1 promoter activity
Since Akt phosphorylation may participate in PDGF inhibi-
tion of ABCA1 expression, we asked whether Akt aﬀected
ABCA1 promoter activity. If so, then the actions of constitu-
tively active Akt, p110 (a subunit of PI3-K), and PTEN (a nat-
ural inhibitor of PI3-K pathway) should aﬀect activity of the
promoter. As predicted, the results (Fig. 5A) showed that con-
stitutively active Akt and p110 suppressed ABCA1 promoter
activity in CRL-2018 cells. In contrast, the co-transfection of
PTEN expression vector activated pABCA1-LUC activity.Fig. 4. PDGF stimulates the phosphorylation of Akt. CRL-2018 cells
were exposed to 10 ng/ml PDGF for 0, 15, 30, 60, 90 and 120 min.
Abundance of phosphorylated Akt was detected by Western blot
analysis using a phospho-speciﬁc Akt antibody (Akt-P, upper portion).
To show equal loading of protein in the each lane, the same blot was
probed a second time with an Akt-speciﬁc antibody.To further conﬁrm the role of Akt, we tested the eﬀects of a
dominant negative mutant of Akt (Akt-DN) on ABCA1 pro-
moter activity (Fig. 5B). Consistent with the above studies;
PDGF inhibited the activity of the ABCA1 promoter and
the expression of Akt-DN inhibited the actions of PDGF on
ABCA1 promoter activity.4. Discussion
In this report, we have summarized the results of studies
showing that PDGF aﬀected ABCA1 gene expression. To con-
nect the actions of Akt with ABCA1 expression, we assessed
the eﬀects of both a constitutively active and a dominant neg-
ative form of Akt on ABCA1 promoter activity (Fig. 5). In
agreement with our hypothesis, constitutively activated Akt
mimiced the inhibitory action of PDGF on ABCA1 promoter
activity and the dominant negative mutant blocked this eﬀect.
Further studies of the role of Akt in PDGF-mediated ABCA1
inhibition will be necessary to deﬁne the pathway by which
PDGF aﬀects the gene.
Since Akt/PKB is one of the downstream components of
intracellular signaling triggered by PDGF, it is not surprising
that Akt/PKB was phosphorylated following treatment of
CRL-2018 cells with PDGF. Akt/PKB phosphorylation is neg-
atively regulated by PTEN/MMAC1/TEP1 a tumor suppres-
sor gene product. This protein is a phosphatase that
dephosphorylates the 3 0 position to reverse the reactions cata-
lyzed by PI3-K [13]. Results in Fig. 5A showed that overex-
pression of PTEN increased ABCA1 promoter activity.
Many studies indicate that phenotypic modulation of SMC
within atherosclerotic lesions is very complex and likely to in-
volve many factors including growth factors and cytokines,
inﬂammatory cell mediators, lipids, lipid peroxidation prod-
ucts, and reactive oxygen species [14,15]. Platelet-derived
Fig. 5. Role of PI3-K/Akt signal transduction pathway on ABCA1 promoter activity by PDGF. (A) Eﬀects of PI3-K components on ABCA1
promoter activity. CRL-2018 cells were transfected with pABCA1-LUC and empty vector (Cont), empty vector plus PDGF-treatment (PDGF), Akt-
CA expression vector (Akt-CA), p110 expression vector (p110), and PTEN expression vector (PTEN). Each data point shows the means ± S.E.M. of
four separate transfections that were performed on separate days. The asterisk denotes a signiﬁcant diﬀerence (P < 0.01). (B) Dominant negative Akt
blocks PDGF inhibition of ABCA1 transcription. CRL-2018 cells were transfected with pABCA1-LUC and empty vector or Akt-DN and then
treated with PDGF. Each data point shows the means ± S.E.M. of four separate transfections that were performed on separate days. The asterisk
denotes a signiﬁcant diﬀerence (P < 0.01).
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tant that functions as an important mediator in the pathogen-
esis of vascular disease [16]. Our studies showed that inhibition
of PI3-K completely blocked the eﬀect of PDGF-suppressed
ABCA1 promoter activity in VSMCs, whereas MEK1 and
PKC inhibitors had no eﬀect on this action, the PI3-K inhibi-
tor LY294002 prevented the suppressive eﬀects of PDGF.
Although those pharmacological probes are relatively selec-
tive, we also veriﬁed the results by using the constitutively ac-
tive form of p110, the subunit of PI3-K and PTEN, the natural
inhibitor of PI3-K pathway. The concordance between the
data using pharmacological probes and the constitutively ac-
tive constructs provides evidence that ABCA1 gene expressionis regulated by a PI3-K-dependent pathway. FoxO transcrip-
tion factors have been implicated in regulating diverse cellular
functions including diﬀerentiation, metabolism, proliferation,
and survival. Furthermore, it is well acknowledged that Akt
mediates many of the eﬀect of growth factors downstream of
PI3-K, and several FoxO proteins are now established sub-
strates of Akt in this pathway [17]. We identiﬁed a putative
FoxO response sequence on ABCA1 promoter by searching
the BLASTN program in a genomic database. Further studies
will be needed to determine the detailed mechanisms involved
in the regulation of the ABCA1 gene.
In summary, the results in this report show that PDGF
inhibits the expression of the endogenous ABCA1 in rat
4376 S. Nagao et al. / FEBS Letters 580 (2006) 4371–4376vascular smooth muscle cell line, CRL-2018. This inhibitory
eﬀect of PDGF on ABCA1 promoter is mediated by PI3-K/
Akt signal transduction pathway. These ﬁndings raise the pos-
sibility that PDGF may aﬀect RTC by controlling ABCA1
expression.References
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